Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Conditions:   Esophageal Neoplasms;   Esophageal Diseases
Interventions:   Radiation: 3-DCRT or IMRT radiation;   Drug: anti-PD-1 antibody SHR-1210
Sponsors:   Hangzhou Cancer Hospital;   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified June 2017

http://ift.tt/2tRO6MK